Altox

Database / Pharmaceutical impurity

Pharmaceutical impurity

Tobramycin EP Impurity A

Tobramycin EP Impurity A is listed in the pharmaceutical impurity collection under CAS 4696-76-8. Its represented structure has formula C18H37N5O10 and a calculated molecular weight of 483.52 g/mol.

2D chemical structure

N H 2 O O H O O O O H H O H 2 N H O H 2 N N H 2 H 2 N O H O H ( R ) ( R ) ( R ) ( S ) ( S ) ( S ) ( R ) ( S ) ( S ) ( R ) ( R ) ( S ) ( R ) ( R ) ( S )

Chemical identity

Catalog name
Tobramycin EP Impurity A
Common name
Tobramycin EP Impurity A
Chemical name
(2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(1R,2S,3S,4R,6S)-4,6-diamino-3-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxyoxane-3,4-diol
CAS
4696-76-8
SMILES
NC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H](N)C[C@@H]2N)[C@H](N)[C@@H](O)[C@@H]1O
InChI
InChI=1S/C18H37N5O10/c19-2-6-11(26)12(27)9(23)17(30-6)32-15-4(20)1-5(21)16(14(15)29)33-18-13(28)8(22)10(25)7(3-24)31-18/h4-18,24-29H,1-3,19-23H2/t4-,5+,6+,7+,8-,9+,10+,11+,12+,13+,14-,15+,16-,17+,18+/m0/s1
InChIKey
SKKLOUVUUNMCJE-FQSMHNGLSA-N
Associated API
Tobramycin

Record ID: Ae4406d3168ae

Computed properties

C18H37N5O10 Molecular formula
483.519 g/molMolecular weight
483.254 DaMonoisotopic exact mass
288.4 ŲTopological polar surface area
-7.325 Calculated LogP (Wildman–Crippen)
109.7608 cm³/molMolar refractivity (Wildman–Crippen)
15 countHydrogen-bond acceptors
11 countHydrogen-bond donors

Descriptors are calculated from the displayed SMILES. Calculated LogP is not a measured partition coefficient or a pH-specific LogD.

Molecular descriptor profile

Descriptor radar

Mol. weight LogP TPSA HBA HBD Rotatable 25 50 75 100

Structural feature counts

0 5 10 15 Count H-bond acceptors H-bond donors Rotatable bonds Rings Aromatic rings Stereo centers

Element composition

C H N O 0 8 16 24 32 Number of atoms

Radar scale: 0–100 percentile within 25,771 distinct represented structures in this release, using the midpoint rank for ties. Larger values indicate a higher descriptor rank, not greater safety or toxicity. Element counts include hydrogen and combine isotopes under each element.

Radar values and percentile reference
DescriptorValuePercentile
Molecular weight483.51983.39
Calculated LogP (Wildman–Crippen)-7.3250.67
Topological polar surface area288.498.45
Hydrogen-bond acceptors1598.18
Hydrogen-bond donors1199.01
Rotatable bonds (strict)669.73

Complete molecular descriptors

PropertyCalculated valueUnit / type
Molecular formulaC18H37N5O10dimensionless
Molecular weight483.519g/mol
Monoisotopic exact mass483.254Da
Topological polar surface area288.4Ų
Calculated LogP (Wildman–Crippen)-7.325dimensionless
Molar refractivity (Wildman–Crippen)109.7608cm³/mol
Hydrogen-bond acceptors15count
Hydrogen-bond donors11count
Rotatable bonds (strict)6count
Heavy atoms33count
Heteroatoms15count
Rings3count
Aromatic rings0count
Aliphatic rings3count
Saturated rings3count
Aromatic heterocycles0count
Aliphatic heterocycles2count
Saturated heterocycles2count
Aromatic carbocycles0count
Aliphatic carbocycles1count
Fraction of sp³ carbon atoms1fraction
Formal charge0e
Disconnected components1count
Isotopically specified atoms0count
Potential atom stereocenters15count
Unspecified atom stereocenters0count
Spiro atoms0count
Bridgehead atoms0count
Labute approximate surface area189.8448Ų
Valence electrons194count
Radical electrons0count
Bertz complexity585.4232index
Balaban J1.7221index

Ring categories overlap and should not be summed. No toxicity result, PDE, HBEL or acceptable intake is inferred from these descriptors.

Toxicological services and resources for Tobramycin EP Impurity A

Qualification and safety assessment of Tobramycin EP Impurity A

Explore toxicological qualification of Tobramycin EP Impurity A and ICH M7 mutagenic impurity assessment of Tobramycin EP Impurity A for evaluation of this impurity in its pharmaceutical context.

Where data gaps need to be addressed, resources include read-across assessment for Tobramycin EP Impurity A and acceptable intake and limit justification for Tobramycin EP Impurity A. The relevant approach depends on the available evidence, exposure and duration of use.

Related Altox services and technical resources

Other catalogue designations with the same represented structure

These are separate catalogue entries; shared structure does not establish interchangeable pharmacopoeial designations.

Identity sources and calculation method

Identifiers originate from the source catalogues and available public identity records. InChI and InChIKey on this page are generated from the displayed SMILES. RDKit validation checks the molecular representation; it does not independently verify every catalogue assignment.

Discuss an assessment for Tobramycin EP Impurity A

Explore Altox services and software through the Altox Pharma-Hub.